Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 505,200 shares, a growth of 8.3% from the August 31st total of 466,600 shares. Based on an average daily trading volume, of 46,500 shares, the days-to-cover ratio is presently 10.9 days. Currently, 8.5% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, HC Wainwright lifted their price target on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.
Get Our Latest Stock Report on Greenwich LifeSciences
Greenwich LifeSciences Stock Down 3.5 %
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). Analysts predict that Greenwich LifeSciences will post -0.81 EPS for the current year.
Insider Activity at Greenwich LifeSciences
In other Greenwich LifeSciences news, CEO Snehal Patel bought 5,500 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were acquired at an average price of $13.18 per share, with a total value of $72,490.00. Following the transaction, the chief executive officer now owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired 11,300 shares of company stock valued at $160,500 over the last quarter. 52.86% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of GLSI. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp purchased a new stake in shares of Greenwich LifeSciences during the second quarter worth approximately $264,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Greenwich LifeSciences by 0.6% during the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
See Also
- Five stocks we like better than Greenwich LifeSciences
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Using the MarketBeat Dividend Tax Calculator
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Most Volatile Stocks, What Investors Need to Know
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.